首页> 外文OA文献 >235O Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial

【2h】

235O Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial

机译：235O在中国铂敏感性复发性卵巢癌（Nora）中尼拉帕里布的疗效和安全性，具有个性化起始剂量：随机，双盲，安慰剂控制，III期试验的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
X. Wu; J. Zhu; R. Yin; J. Yang; J. Liu; J. Wang; L. Wu; Z. Liu; Y. Gao; D. Wang; G. Lou; H. Yang; Q. Zhou; B. Kong; Y. Huang; L. Chen; G. Li; R. An; K. Wang; Y. Zhang;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer [J] . AghajanianC., BlankS.V., GoffB.A., Journal of Clinical Oncology . 2012,第17期

机译：海洋学：铂敏感性复发性上皮性卵巢癌，原发性腹膜癌或输卵管癌患者中，有或没有贝伐单抗的随机，双盲，安慰剂对照的Ⅲ期化疗试验
2. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse [J] . Vergote Ignace, Armstrong Deborah, Scambia Giovanni, Journal of Clinical Oncology . 2016,第19期

机译：一项随机，双盲，安慰剂对照的Ⅲ期研究，旨在评估每周法格妥珠单抗联合卡铂和紫杉烷治疗卵巢癌患者首次铂敏感性复发的疗效和安全性
3. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial [J] . Ledermann Jonathan A., Harter Philipp, Gourley Charlie, The lancet oncology . 2016,第11期

机译：接受olaparib维持单药治疗的铂敏感性复发性浆液性卵巢癌患者的整体生存：一项来自随机，安慰剂对照，双盲，2期试验的更新分析
4. Analysis on the Efficacy and Safety of the Patients with Advanced Ovarian Cancer [C] . Yunxia Xue, Xingyun Sun, Peijing Shi International Forum on Bioinformatics and Medical Engineering . 2015

机译：晚期卵巢癌患者的疗效和安全性分析
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. OCEANS: A Randomized Double-Blind Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancer [O] . Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff, -1

机译：海洋：铂敏感性复发性上皮性卵巢癌原发性腹膜癌或输卵管癌患者中有或无贝伐单抗的随机双盲安慰剂对照的Ⅲ期化学治疗
7. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial [O] . Jonathan A Ledermann, Philipp Harter, Charlie Gourley, 2016

机译：铂敏感复发性浆液癌患者的整体生存接受Olaparib维持单药治疗：从随机，安慰剂控制，双盲，第2期试验的更新分析

235O Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial

著录项

引文网络

相似文献

相关主题

期刊订阅